Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018
02. Februar 2018 16:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 36th Annual Healthcare Conference on January 10, 2018
22. Dezember 2017 09:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017
08. November 2017 16:16 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
07. November 2017 07:01 ET
|
Keryx Biopharmaceuticals, Inc.
Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysisOne in seven...
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results
07. November 2017 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Company reported $15.0 million in third quarter 2017 total revenues, including net U.S. Auryxia® product sales of $13.6 millionU.S. Food and Drug Administration (FDA) approves Auryxia® (ferric...
Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
06. November 2017 16:31 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
04. November 2017 11:00 ET
|
Keryx Biopharmaceuticals, Inc.
NEW ORLEANS, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today presented new...
Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia® (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease
02. November 2017 18:55 ET
|
Keryx Biopharmaceuticals, Inc.
Oral presentation showed impact of ferric citrate on a phosphate-regulating hormone, FGF23Poster presentation showed effect of ferric citrate when dosed to increase hemoglobin on serum phosphorus in...
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017
26. Oktober 2017 16:15 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting
13. Oktober 2017 10:10 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that three...